Page 2 - Nasdaq Cnce News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zacks Investment Research cut shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small […]

StockNews.com started coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) in a research report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock. A number of other research analysts have also recently commented on the company. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a […]